共查询到20条相似文献,搜索用时 15 毫秒
1.
This article provides an update on depression and apathy in Parkinson’s disease (PD), both of which are common but often misunderstood.
The diagnosis of depression in PD can be challenging and we still do not have solid evidence on which to base our treatment
decisions. Apathy is most commonly seen in the setting of dementia or depression but emerging evidence suggests that it may
be a core feature of PD. There are conflicting reports about the effects of deep brain stimulation (DBS) on mood and apathy,
but studies suggest that at least some patients may develop depression and apathy after the procedure. Although we are making
strides toward a better understanding of depression and apathy in PD, it is clear that more research is needed about these
non-motor features. 相似文献
2.
Abstract
Objectives
The pathophysiology of depression and anxiety in Parkinson's disease remains obscure. We aimed to compare the fractional anisotropy
(FA) values of Parkinson's disease (PD) patients with and without depression to investigate the nature of depression in PD.
Methods
Twenty-eight patients were divided into two groups: those with depression and those without. Diagnosis of depression was made
using the DSM-IV criteria. Patients in the two groups were matched for Hoehn Yahr stage.
Results
There were significant reductions in FA values in the bilateral frontal ROIs possibly representing anterior cingulate bundles.
Conclusions
The anterior cingulate bundles play an important role in depression in PD, and some aspects of depression in PD have pathological
processes in common with de novo depression. 相似文献
3.
Depression is common in Parkinson’s disease (PD), and its identification and treatment are critically important in disease
management. Despite depression’s high prevalence and major impact on patient quality of life, questions remain regarding its
epidemiology and preferred treatment. The authors of this paper summarize available information on the epidemiology of depression
in PD, review treatment options, and discuss possible interactions between antidepressants and other agents. This information
may help guide clinical treatment and define the need for further studies. 相似文献
4.
Among the recently well appreciated non-motor symptoms in Parkinson’s disease (PD), depression plays a prominent role due to its frequency and impact on quality of life. However, depression may be confounded by motor symptoms, especially akinesia and other non-motor symptoms such as apathy, anxiety and dementia. Data on specific diagnostic tools or treatment for depressive symptoms in PD patients are still sparse. Here we summarize an expert opinion based on available data and clinical experience. 相似文献
5.
Abstract.
Relatively little has been published in the international
literature concerning the caregiving-related problems associated
with Parkinsons disease. We therefore undertook two exploratory
studies that have allowed us to identify the needs and specific
problems perceived by such caregivers in both qualitative and
quantitative terms. 相似文献
7.
Rifampicin is a macrocyclic antibiotic used extensively for the treatment of Mycobacterium tuberculosis and other mycobacterial infections. Recently, it was discovered that rifampicin exhibits neuroprotective effects. It has been shown to protect PC12 cells against MPP +-induced apoptosis and inhibit the expression of α-synuclein multimers. In in vitro studies, rifampicin pretreatment protects PC12 cells against rotenone-induced cell death. Qualitative and quantitative analyses uncover that rifampicin significantly suppresses rotenone-induced apoptosis by ameliorating mitochondrial oxidative stress. It reduces microglial inflammation and improves neuron survival. Our results indicate that rifampicin is cytoprotective under a variety of experimental conditions, and suggest that it may be useful in PD therapeutics. It is the aim of this paper to review the experimental neuroprotection data reported using rifampicin with a focus on the molecular and cellular mechanisms of cytoprotective effect in in vitro models of PD. 相似文献
8.
Totally three articles focusing on bone marrow mesenchymal stem cells alleviating PC12 cytotoxicity induced by 6-hydroxydopamine and intracerebroventricular transplantation of non-modified/gene-modified 相似文献
9.
Totally three articles focusing on gene therapy of Parkinson’s disease, the effect of levodopa on toxicity of dopaminergic neurons in substantia nigra and striatum, and the effect of rifampicin on reducing Parkinson’s disease-induced dopaminergic neuronal apoptosis 相似文献
10.
Parkinson’s disease is a neurodegenerative disease characterised by a massive loss of dopaminergic neurons in the substantia nigra. Yet glial cells may also participate in the pathophysiology of the disease. Indeed, glial cells can produce trophic factors which may stimulate neuronal survival or, alternatively, they could produce toxic compounds which may be involved in neuronal degeneration. This paper reviews the potentially protective or deleterious effects of glial cells in the substantia nigra of patients with Parkinson’s disease. 相似文献
11.
Journal of Neurology - Parkinson’s disease (PD) is the second commonest neurodegenerative disorder in the world with a rising prevalence. The pathophysiology is multifactorial but aggregation... 相似文献
13.
Objectives To determine
whether there are gender differences
in the Parkinson’s disease
(PD) phenotype using a large
clinic–based cohort.
Methods We
examined gender differences in demographic,
historical and clinical
characteristics in a consecutive
clinical series of 1264 individuals
diagnosed with PD.
Results The
majority of individuals in the sample
were male (67 %). Comparative
analyses showed males and females
were not significantly different on
most demographic and historical
characteristics. For both genders,
the mean age and the mean age at
symptomatic onset were about 70
and 63 years, respectively and, thus,
disease duration was not significantly
different between genders.
The proportion of individuals with
a positive family history of PD
(15 %) was similar for both genders.
A positive history of depression
was significantly higher in females
(35 % vs. 24 %). The UPDRS
instability score was significantly
worse among females, whereas the
rigidity score was significantly
worse for males. Females showed
significantly worse ADL capacity
and a more advanced H&Y stage.
The proportion of individuals receiving
antiparkinsonian medication
(about 66 %) and time between
the last dose and the clinical
evaluation (about 4 hours) was
similar for both genders. There was
a trend for lower daily levodopa
equivalence dosage and more severe
dyskinesia score among females
but these differences did not
reach statistical significance after
Bonferroni correction.
Conclusions The majority of comparisons
tended to highlight the commonalities
in the PD phenotype between
genders, particularly in reference
to historical and early disease stage
characteristics. However, gender
may be an important factor related
to the expression of PD features
during the symptomatic disease
course. 相似文献
14.
Journal of Neurology - Recently, there has been a surge in awareness of the gastrointestinal microbiome (GM) and its role in health and disease. Of particular note is an association between the GM... 相似文献
15.
Astrocytes play direct, active, and critical roles in mediating neuronal survival and function in various neurodegenerative
disorders. This role of astrocytes is well illustrated in amyotrophic lateral sclerosis (ALS), in which the removal of glutamate
from the extracellular space by astrocytes confers neuroprotection, whereas astrocytic release of soluble toxic molecules
promotes neurodegeneration. In recent years, this context-dependent dual role of astrocytes has also been documented in experimental
models of Parkinson’s disease. The present review addresses these studies and some potential mechanisms by which astrocytes
may influence the neurodegenerative processes in Parkinson’s disease, and in particular examines how astrocytes confer neuroprotection
either through the removal of toxic molecules from the extracellular space or through the release of trophic factors and antioxidant
molecules. In contrast, under pathological conditions, astrocytes release proinflammatory cytokines and other toxic molecules
that are detrimental to dopaminergic neurons. These emerging roles of astrocytes in the pathogenesis of Parkinson’s disease
constitute an exciting development with promising novel therapeutic targets. 相似文献
16.
Much of our current knowledge about depression in Alzheimer’s disease and other dementias is based on the 1991 National Instiute
of Health Consensus Development Panel on the Diagnosis and Treatment of Depression in Late Life, and its subsequent 1997 update.
However, much research has taken place since these reports. This article summarizes this research, particularly research that
has taken place in the past year. Comorbid depression is common in all types of dementia. It may, however, appear to be different
from classic depression. Unlike classic depression, the depression found in dementia may result from anatomic damage to the
brain. This is most clearly demonstrated in vascular depression. The implications of this are many. Treatments for depression
are designed for classic depression. For those with vascular depression (and other depressions associated with dementia) treatments
may not be as efficacious. Newer strategies, including agents not commonly thought of as antidepressants, may be needed. 相似文献
18.
SNpc neurons are uniquely at risk from damage by a variety of ROS, including catechol-quinones formed from autoxidation of DA; as well as Tyr O ., TyrOOH, H 2O 2, O 2−., NO ., HONOO −, and HO .. The high content of Fe 2+ in SNPc neurons further promotes HO . formation. Self-preservation ensures that SNpc cells are endowed with a battery of cellular antioxidants, which deactivate these cytotoxic species. Most notable are catalase, superoxide dismutase; and DT-diaphorase, which catalyzes a 2-electron reduction of catechol-quinones. Intra mitochondrial MAO can serve to protect or to damage SNpc neurons, depending on the cellular environ at any time. Newer treatment approaches towards PD include the addition of nutrients such as vitamin E and addition of antioxidant drugs that may already be in use as antiparkinsonians: deprenyl, amantadine, DA D 2 agonists, apomorphine, NMDA- and adenosine A2A-antagonists. Finally, the potential of neural transplants is explored in the proposal that Sertoli cells, or specific neural cells, or placental blood stem cells will find “routine” use instead of fetal neural cells in the treatment of last-resort for PD. 相似文献
19.
Summary. Heart rate variability (HRV) decrease in Parkinsons disease (PD) could only be a consequence of reduce motor activity besides of being a marker of cardiovascular dysautonomia. Under continuously recorded and standardised motor activity, we studied thirty patients compared to controls in 3 PD stages: group I: less than 2 year-evolution, slight impaired without L-dopa; group II: mildly impaired with L-dopa; group III: advanced PD with motor complications. No difference was observed between group I and controls. The diurnal low frequency power (LF) and the ratio of LF/high frequency (HF) power decreased in groups II and III. The nocturnal vagal indicators: HF power and pNN50 were decreased in group III. Those parameters were correlated with Off-drug-motor handicap, suggesting an evolutive HRV decrease with disease severity but not with On-drug-motor activity. The low LF despite the higher motor activity in group III, due to dyskinesias, suggested a defective cardiovascular up-regulation.Received January 15, 2003; accepted April 9, 2003
Published online June 10, 2003 相似文献
|